These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10912165)

  • 41. Enoxacin: clinical results in lower respiratory tract infections.
    Grassi C; Mangiarotti P; Dal Prà ML
    J Chemother; 1989 Jul; 1(4 Suppl):790-2. PubMed ID: 16312641
    [No Abstract]   [Full Text] [Related]  

  • 42. Information from your family doctor. When antibiotics can help.
    American Academy of Family Physicians
    Am Fam Physician; 2006 Sep; 74(6):969. PubMed ID: 17002030
    [No Abstract]   [Full Text] [Related]  

  • 43. [Therapeutic use of fluoroquinolones].
    Lumio J
    Duodecim; 1999; 115(3):304-15. PubMed ID: 11830877
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of clonality in the global spread of fluoroquinolone-resistant bacteria.
    Klugman KP
    Clin Infect Dis; 2003 Mar; 36(6):783-5. PubMed ID: 12627363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections.
    Shah P; Trostmann U; Tack K
    Int J Antimicrob Agents; 2002 Mar; 19(3):245-8. PubMed ID: 11932150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The rational use of fluoroquinolones].
    Zhang Y
    Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):7-8. PubMed ID: 12795261
    [No Abstract]   [Full Text] [Related]  

  • 47. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.
    Soejima R; Niki Y; Kishomoto T; Kimura M; Kubota Y
    Drugs; 1995; 49 Suppl 2():257-9. PubMed ID: 8549323
    [No Abstract]   [Full Text] [Related]  

  • 48. [Fluoroquinolone. 2. Pharmacokinetics and clinical use].
    Kemmerich B; Stahlmann R; Lode H
    Dtsch Med Wochenschr; 1988 Apr; 113(17):693-5. PubMed ID: 3282865
    [No Abstract]   [Full Text] [Related]  

  • 49. [Which partner for the betalactam agent in empiric combined therapy? I Fluoroquinolone].
    Bedos JP
    Ann Fr Anesth Reanim; 2004 Jun; 23(6):636-8. PubMed ID: 15234734
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical evaluation of a new antibacterial agent, xibornol, in the treatment of bacterial infections of the upper respiratory tract in childhood. Comparison with erythromycin].
    Capristo AF; Maiello N; Coppola T; Decimo F; Miraglia del Giudice M; Antignani RG
    Minerva Pediatr; 1986 Jun; 38(11-12):503-10. PubMed ID: 3526110
    [No Abstract]   [Full Text] [Related]  

  • 51. Infections of the upper respiratory tract, head, and neck. The role of anaerobic bacteria.
    Brook I
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):37-48. PubMed ID: 19667548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The newer fluoroquinolones.
    O'Donnell JA; Gelone SP
    Infect Dis Clin North Am; 2004 Sep; 18(3):691-716, x. PubMed ID: 15308282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic strategies involving antimicrobial treatment of the lower respiratory tract in small animals.
    McKiernan BC
    J Am Vet Med Assoc; 1984 Nov; 185(10):1155-8. PubMed ID: 6392245
    [No Abstract]   [Full Text] [Related]  

  • 54. [Chronic obstructive respiratory tract diseases: standards and trends of antibiotic therapy].
    Feist H; Armbruster C; Kapfhammer G; Vetter N; Drlicek M; Hackl H
    Prax Klin Pneumol; 1988 Jul; 42(7):529-32. PubMed ID: 3186652
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of the clinical microbiology profile of moxifloxacin.
    Krasemann C; Meyer J; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S51-63. PubMed ID: 11249830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Microbial sensitivity to ambazone (Faringosept) in pharyngeal samples from patients with acute infections of the upper respiratory tract].
    Fulga I; Neguţ M; Năşcuţiu AM; Nemet C; Toma F; Grigore L; Niţescu R; Marcu C; Nedelcu L; Spircu T
    Bacteriol Virusol Parazitol Epidemiol; 2007; 52(1-2):19-27. PubMed ID: 18441955
    [No Abstract]   [Full Text] [Related]  

  • 57. Balofloxacin Choongwae.
    Alksne L
    Curr Opin Investig Drugs; 2003 Feb; 4(2):224-9. PubMed ID: 12669387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moxifloxacin Bayer.
    Barrett JF
    Curr Opin Investig Drugs; 2000 Sep; 1(1):45-51. PubMed ID: 11249594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Use of new quinolones in respiratory infections].
    Sanz Moreno J; Jiménez Rodríguez A
    Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.